Nature Commun: Hard-core prevention of HIV, is AIDS still an "incurable disease"?

On June 5, 1981, the US Centers for Disease Control and Prevention published a case report of 5 AIDS patients, which was the first official record of AIDS in the world

To end AIDS, prevention is one of the focuses of scientists

In the current situation where HIV prevention vaccines have not been successfully developed, pre-exposure prophylaxis (PrEP), mainly antiretroviral therapy (ART), is a means to slow down the AIDS epidemic.

In this study, the researchers first evaluated the ability of Leronlimab to inhibit the spread of HIV virus between cells in an in vitro diffusion test.

Test results show: Leronlimab blocked the spread of CCR5 in vitro

The test results showed that all animals showed good tolerance to Leronlimab without adverse clinical reactions, which confirmed its high safety reported in multiple previous clinical trials

Leronlimab as the test procedure and results of PrEP

The study mentioned at the end that Leronlimab can be administered subcutaneously at home, which is more advantageous than other intramuscular injections that need to be administered in the clinic

In view of the fact that the CCR5 Δ32/Δ32 phenotype can resist HIV infection without threatening life, and the safety of Leronlimab has also been further verified.

Original source:

Chang, XL, Webb, GM, Wu, HL et al.